Iranian Journal of Pathology

An Insight into Prognostic Impact of TIPE2 & CD36 Immunohistochemical Expression in Urothelial Carcinoma

Document Type : Original Research

Authors

Amira M. Abd El Maged 1
Nahla Mustafa Badr 1
Hanan Lotfy Mohamed 2

1 Pathology Department, Faculty of Medicine, Menoufia University, Shebin El Kom, Egypt

2 Department of pathology, Faculty of Medicine, Zagazig University, Egypt

https://doi.org/10.30699/ijp.2024.2029525.3301
Abstract
Background & Objective: Even though fast advances in the detection and management of bladder carcinoma, the number of deaths remains high. Therefore, the identification of an effective biomarker predicting tumor progression in cancer bladder patients is a crucial issue. This study aims to identify TIPE2 and CD36 expressions in cancer bladder and examine their relationship with clinicopathological data and prognosis.
Methods: Using immunohistochemistry, we investigated 60 specimens of bladder urothelial cancer (UC) for the expression of TIPE2 and CD36 and compared them with clinicopathologic parameters and survival data. Furthermore, we investigate the association between TIPE2 and CD36 expression and Vimentin expression to elucidate the influence of TIPE2 and CD36 on the epithelial-mesenchymal transition (EMT) in UC.
Results: TIPE2 expression was associated with lower stages and prolonged disease-free survival (DFS) and overall survival (OS). Therefore, TIPE2 may be considered a good indicator of UC prognosis. CD36 immuno-positivity was associated with high tumor grade, stages, shorter OS, and DFS. Therefore, the immune positivity of CD36 may be a poor prognostic marker for UC patients. Furthermore, Vimentin expression was directly correlated with CD36 expression and inversely correlated with TIPE2 expression.
Conclusion: TIPE2 and CD36 may be novel biomarkers for predicting tumor metastasis and prognosis in patients with bladder UC and hold promise as therapeutic targets.

Highlights

  • Positive TIPE2 immunohistochemical expression is associated with good prognostic factors of urothelial carcinoma (UC).
  • Positive CD36 immunohistochemical expression is associated with poor prognostic factors of UC.
  • High TIPE2 immunostaining is associated with negative vimentin expression.
  • High CD36 immunostaining is associated with positive vimentin expression.
  • The current results suggest that TIPE2 and CD36 may influence UC metastasis through epithelial-mesenchymal transition.
  • Negative TIPE2 and positive CD36 immunostaining may be beneficial tools for predicting cancer aggressiveness and metastasis and detecting outcomes of UC. They may also serve as potential therapeutic targets.

Keywords

Urothelial carcinoma
TIPE2
CD36
Immunohistochemistry
epithelial-mesenchymal transition
Prognosis

Subjects

  1. Siegel RL, Miller KD, Fuchs HE, Jemal AJCacjfc. Cancer statistics, 2022. 2022. [DOI:10.3322/caac.21708] [PMID]
  2. Netto GJ, Amin MB, Berney DM, Comperat EM, Gill AJ, Hartmann A, et al. The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Prostate and Urinary Tract Tumors. Eur Urol. 2022;82(5):469-82. [DOI:10.1016/j.eururo.2022.07.002] [PMID]
  3. Jiang Y, Zhang Z, Wang X, Feng Z, Hong B, Yu D, et al. A Novel Prognostic Factor TIPE2 in Bladder Cancer. Pathol Oncol Res. 2022;28:1610282. [DOI:10.3389/pore.2022.1610282] [PMID]
  4. Bordoloi D, Banik K, Shabnam B, Padmavathi G, Monisha J, Arfuso F, et al. TIPE Family of Proteins and Its Implications in Different Chronic Diseases. Int J Mol Sci. 2018;19(10):2974. [DOI:10.3390/ijms19102974] [PMID]
  5. Freundt EC, Bidere N, Lenardo MJ. A different TIPE of immune homeostasis. Cell. 2008;133(3):401-2. [DOI:10.1016/j.cell.2008.04.017] [PMID]
  6. Zhang G, Hao C, Lou Y, Xi W, Wang X, Wang Y, et al. Tissue-specific expression of TIPE2 provides insights into its function. Mol Immunol. 2010;47(15):2435-42. [DOI:10.1016/j.molimm.2010.06.016] [PMID]
  7. Lu Q, Liu Z, Li Z, Chen J, Liao Z, Wu WR, et al. TIPE2 Overexpression Suppresses the Proliferation, Migration, and Invasion in Prostate Cancer Cells by Inhibiting PI3K/Akt Signaling Pathway. Oncol Res. 2016;24(5): 305-13. [DOI:10.3727/096504016X14666990347437] [PMID]
  8. Li Z, Guo C, Liu X, Zhou C, Zhu F, Wang X, et al. TIPE2 suppresses angiogenesis and non-small cell lung cancer (NSCLC) invasiveness via inhibiting Rac1 activation and VEGF expression. Oncotarget. 2016;7(38):62224-39. [DOI:10.18632/oncotarget.11406] [PMID]
  9. Buckley D, Duke G, Heuer TS, O'Farrell M, Wagman AS, McCulloch W, et al. Fatty acid synthase - Modern tumor cell biology insights into a classical oncology target. Pharmacol Ther. 2017;177:23-31. [DOI:10.1016/j.pharmthera.2017.02.021] [PMID]
  10. Pascual G, Avgustinova A, Mejetta S, Martin M, Castellanos A, Attolini CS, et al. Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature. 2017;541(7635):41-5. [DOI:10.1038/nature20791] [PMID]
  11. Ladanyi A, Mukherjee A, Kenny HA, Johnson A, Mitra AK, Sundaresan S, et al. Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene. 2018;37(17):2285-301. [DOI:10.1038/s41388-017-0093-z] [PMID]
  12. Wang J, Li Y. CD36 tango in cancer: signaling pathways and functions. Theranostics. 2019;9(17):4893-908. [DOI:10.7150/thno.36037] [PMID]
  13. Jiang M, Wu N, Xu B, Chu Y, Li X, Su S, et al. Fatty acid-induced CD36 expression via O-GlcNAcylation drives gastric cancer metastasis. Theranostics. 2019;9(18):5359-73. [DOI:10.7150/thno.34024] [PMID]
  14. Yoshida T, Yokobori T, Saito H, Kuriyama K, Kumakura Y, Honjo H, et al. CD36 Expression Is Associated with Cancer Aggressiveness and Energy Source in Esophageal Squamous Cell Carcinoma. Ann Surg Oncol. 2021;28(2):1217-27. [DOI:10.1245/s10434-020-08711-3] [PMID]
  15. Ji Z, Shen Y, Feng X, Kong Y, Shao Y, Meng J, et al. Deregulation of Lipid Metabolism: The Critical Factors in Ovarian Cancer. Front Oncol. 2020;10:593017. [DOI:10.3389/fonc.2020.593017] [PMID]
  16. Wang R, Tao B, Fan Q, Wang S, Chen L, Zhang J, et al. Fatty-acid receptor CD36 functions as a hydrogen sulfide-targeted receptor with its Cys333-Cys272 disulfide bond serving as a specific molecular switch to accelerate gastric cancer metastasis. EBioMedicine. 2019;45:108-23. [DOI:10.1016/j.ebiom.2019.06.037] [PMID]
  17. Cheng Q, Jabbari K, Winkelmaier G, Andersen C, Yaswen P, Khoshdeli M, et al. Overexpression of CD36 in mammary fibroblasts suppresses colony growth in breast cancer cell lines. Biochem Biophys Res Commun. 2020;526(1):41-7. [DOI:10.1016/j.bbrc.2020.03.061] [PMID]
  18. Pan J, Fan Z, Wang Z, Dai Q, Xiang Z, Yuan F, et al. CD36 mediates palmitate acid-induced metastasis of gastric cancer via AKT/GSK-3beta/beta-catenin pathway. J Exp Clin Cancer Res. 2019;38(1):52. [DOI:10.1186/s13046-019-1049-7] [PMID]
  19. Zhang Y, Weinberg RA. Epithelial-to-mesenchymal transition in cancer: complexity and opportunities. Front Med. 2018;12(4):361-73. [DOI:10.1007/s11684-018-0656-6] [PMID]
  20. Deng M, Cai X, Long L, Xie L, Ma H, Zhou Y, et al. CD36 promotes the epithelial-mesenchymal transition and metastasis in cervical cancer by interacting with TGF-beta. J Transl Med. 2019;17(1):352. [DOI:10.1186/s12967-019-2098-6] [PMID]
  21. Drury J, Rychahou PG, Kelson CO, Geisen ME, Wu Y, He D, et al. Upregulation of CD36, a Fatty Acid Translocase, Promotes Colorectal Cancer Metastasis by Increasing MMP28 and Decreasing E-Cadherin Expression. Cancers (Basel). 2022;14(1):252. [DOI:10.3390/cancers14010252] [PMID]
  22. Wu J, Zhang H, Xu C, Xu H, Zhou X, Xie Y, et al. TIPE2 functions as a metastasis suppressor via negatively regulating beta-catenin through activating GSK3beta in gastric cancer. Int J Oncol. 2016;48(1): 199-206. [DOI:10.3892/ijo.2015.3224] [PMID]
  23. Zhu L, Zhang X, Fu X, Li Z, Sun Z, Wu J, et al. TIPE2 suppresses progression and tumorigenesis of esophageal carcinoma via inhibition of the Wnt/beta-catenin pathway. J Transl Med. 2018;16(1):7. [DOI:10.1186/s12967-018-1383-0] [PMID]
  24. Liu Y, Wang X, Wan L, Liu X, Yu H, Zhang D, et al. TIPE2 inhibits the migration and invasion of endometrial cells by targeting beta-catenin to reverse epithelial-mesenchymal transition. Hum Reprod. 2020;35(6):1377-90. [DOI:10.1093/humrep/deaa062] [PMID]
  25. Jeong H, Oh HE, Kim H, Lee JH, Lee ES, Kim YS, et al. Upregulation of Fatty Acid Transporters is Associated With Tumor Progression in Non-Muscle-Invasive Bladder Cancer. Pathol Oncol Res. 2021;27:594705. [DOI:10.3389/pore.2021.594705] [PMID]
  26. Zhang X, Cao G, Diao X, Bai W, Zhang Y, Wang S. Vimentin Protein In Situ Expression Predicts Less Tumor Metastasis and Overall Better Survival of Endometrial Carcinoma. Dis Markers. 2022;2022: 5240046. [DOI:10.1155/2022/5240046] [PMID]
  27. Jia W, Li Z, Chen J, Sun L, Liu C, Wang S, et al. TIPE2 acts as a biomarker for tumor aggressiveness and suppresses cell invasiveness in papillary thyroid cancer (PTC). Cell Biosci. 2018;8:49. [DOI:10.1186/s13578-018-0247-x] [PMID]
  28. Lin Z, Liu W, Xiao C, Fan Y, Zhuang G, Qi Z. TIPE2 inhibits GC via regulation of cell proliferation, apoptosis and inflammation. Oncol Rep. 2018;40(3):1307-16. [DOI:10.3892/or.2018.6576] [PMID]
  29. Li XM, Su JR, Yan SP, Cheng ZL, Yang TT, Zhu Q. A novel inflammatory regulator TIPE2 inhibits TLR4-mediated development of colon cancer via caspase-8. Cancer Biomark. 2014;14(4):233-40. [DOI:10.3233/CBM-140402] [PMID]
  30. Pardo JC, Sanhueza T, Ruiz de Porras V, Etxaniz O, Rodriguez H, Martinez-Cardus A, et al. Prognostic Impact of CD36 Immunohistochemical Expression in Patients with Muscle-Invasive Bladder Cancer Treated with Cystectomy and Adjuvant Chemotherapy. J Clin Med. 2022;11(3):497. [DOI:10.3390/jcm11030497] [PMID]
  31. Nath A, Chan C. Genetic alterations in fatty acid transport and metabolism genes are associated with metastatic progression and poor prognosis of human cancers. Sci Rep. 2016;6(1):18669. [DOI:10.1038/srep18669] [PMID]
  32. Bowden M, Nadal R, Zhou CW, Werner L, Barletta J, Juanpere N, et al. Transcriptomic analysis of micropapillary high grade T1 urothelial bladder cancer. Sci Rep. 2020;10(1):20135. [DOI:10.1038/s41598-020-76904-7] [PMID]
Iranian Journal of Pathology
Volume 20, Issue 1
Winter 2025
Pages 58-67

  • Receive Date 25 May 2024
  • Revise Date 19 July 2024
  • Accept Date 07 November 2024

Home

Guide for Authors

Submit Manuscript

Contact Us